Allarity Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
January 20, 2023 16:01 ET
|
Allarity Therapeutics, Inc.
Press release Boston, MA U.S.A. (January 20, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together...
Allarity Therapeutics Reschedules 2022 Annual Stockholders Meeting and Sets New Record Date
December 01, 2022 16:25 ET
|
Allarity Therapeutics, Inc.
PRESS RELEASE Boston, MA U.S.A. (December 1, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together...
Allarity Therapeutics Reports Third Quarter 2022 Financial Results
November 15, 2022 16:01 ET
|
Allarity Therapeutics, Inc.
Press release Cambridge, MA U.S.A. (November 15, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics...
Allarity Therapeutics Announces Adjournment of 2022 Annual Meeting of Stockholders
November 07, 2022 18:15 ET
|
Allarity Therapeutics, Inc.
Press release Cambridge, MA U.S.A. (November 7, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics...
Allarity Therapeutics Reports Second Quarter 2022 Financial Results, Provides Recent Operational Highlights, and Regains Compliance with NASDAQ Listing Requirements
October 11, 2022 16:05 ET
|
Allarity Therapeutics, Inc.
Cambridge, MA U.S.A. (October 11, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with...
Allarity Therapeutics Appoints Seasoned Biotechnology Executive Jerry McLaughlin to Board of Directors
September 26, 2022 06:00 ET
|
Allarity Therapeutics, Inc.
Press release Cambridge, MA U.S.A. (September 26, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology...
Allarity Therapeutics to Present at Ladenburg Thalmann Healthcare Conference
September 16, 2022 06:00 ET
|
Allarity Therapeutics, Inc.
Press release Cambridge, MA U.S.A. (September 16, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology...
Allarity Therapeutics Announces Appointment of New Auditor
September 12, 2022 16:10 ET
|
Allarity Therapeutics, Inc.
Press release Cambridge, MA U.S.A. (September 12, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel...
Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)
August 26, 2022 16:30 ET
|
Allarity Therapeutics, Inc.
Press release Cambridge, MA U.S.A. (August 26, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel...
Allarity Therapeutics Refocuses Oncology Pipeline Strategy Towards Combination Therapies
August 02, 2022 06:00 ET
|
Allarity Therapeutics, Inc.
New strategy aligns with ongoing shift in oncology standard-of-caretowards combination therapies Combination therapy focus expected to improve the Company’s future funding and commercial...